Clinical Trials on Waldenstrom Macroglobulinemia (WM)

Total 348 results

Vertex Pharmaceuticals Incorporated

Completed

Trial of AVN-944 in Patients With Advanced Hematologic Malignancies

Multiple Myeloma | Hodgkin's Lymphoma | Non-Hodgkin's Lymphoma | Waldenstrom's Macroglobulinemia | Acute Leukemia | Chronic Leukemia

United States
BeiGene

Recruiting

Observational Study Evaluating the Efficacy and Safety of Zanubrutinib in Participants With Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States, Puerto Rico
Shayna Sarosiek, MD
ADC Therapeutics S.A.

Recruiting

Loncastuximab Tesirine in WM

Waldenstrom Macroglobulinemia

United States
Fundación Española de Hematología y Hemoterapía

Recruiting

Spanish Registry of Patients With IgM Monoclonal Gammopathies (PRAME)

Waldenstrom Macroglobulinemia

Spain
University College, London
Janssen-Cilag Ltd.

Recruiting

Rituximab and Ibrutinib (RI) Versus Dexamethasone, Rituximab and Cyclophosphamide (DRC) as Initial Therapy for Waldenström's Macroglobulinaemia (RAINBOW)

Waldenstrom Macroglobulinemia

United Kingdom
Christian Buske
Hoffmann-La Roche; Johnson & Johnson; ClinAssess GmbH; University of Ulm; Zentrum...

Active, not recruiting

Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

Waldenstrom Macroglobulinemia

Germany, Greece
Janssen Research & Development, LLC

Completed

A Study of Ibrutinib (PCI-32765) in Chinese Participants With Relapse or Refractory Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

China
University College, London
Merck Sharp & Dohme LLC

Completed

Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia (PembroWM)

Waldenstrom Macroglobulinemia

United Kingdom
Dana-Farber Cancer Institute
AbbVie

Completed

Study of ABT-199 (GDC-199) In Patients With Relapsed Or Refractory Waldenström Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Assistance Publique - Hôpitaux de Paris

Completed

Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia (WM2)

Waldenstrom Macroglobulinemia

France
University of Arkansas

Terminated

DT PACE, Tandem Autologous Transplant, Maintenance Therapy for Waldenstrom's Macroglobulinemia Patients

Waldenstrom Macroglobulinemia

United States
University of Arkansas
Celgene Corporation

Completed

Anti-Angiogenesis Therapy Using Thalidomide in Patients With Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Jonsson Comprehensive Cancer Center
Genentech, Inc.

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Canada
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S9805, High-Dose Melphalan Plus Peripheral Stem Cell Transplantation Followed by Interferon Alfa in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Herbert Irving Comprehensive Cancer Center
National Cancer Institute (NCI)

Unknown

Collecting Stem Cells in Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Rituximab in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Puerto Rico, South Africa
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab Plus Fludarabine in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States, Canada, United Kingdom, Sweden
National Cancer Institute (NCI)

Recruiting

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib and Rituximab) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Rituximab, Combination Chemotherapy, and 90-Yttrium Ibritumomab Tiuxetan for Patients With Stage I or II Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia | Testicular Lymphoma | Contiguous Stage II Adult Diffuse Large Cell Lymphoma | Noncontiguous Stage II Adult Diffuse... and other conditions

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Terminated

Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed Waldenstrom's Macroglobulinemia

Lymphoma

United States
Taunton and Somerset Hospital

Completed

Chlorambucil or Fludarabine as First-Line Therapy in Treating Patients With Previously Untreated Waldenström Macroglobulinemia, Splenic Lymphoma, or Lymphoplasmacytic Lymphoma

Lymphoma

Australia, United Kingdom
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Dana-Farber Cancer Institute
AbbVie; Pharmacyclics LLC.

Active, not recruiting

Ibrutinib + Venetoclax in Untreated WM

Waldenstrom Macroglobulinemia | MYD88 Gene Mutation

United States
Burzynski Research Institute

Withdrawn

Antineoplaston Therapy in Treating Patients With Recurrent or Refractory Waldenstrom's Macroglobulinemia

Waldenstrom Macroglobulinemia

United States
Seoul National University Hospital
Seoul National University Bundang Hospital

Unknown

Study of VTD in Waldenstrom's Macroglobulinemia (BOMB-THROW)

Waldenstrom Macroglobulinemia | Lymphoplasmacytic Lymphoma

Korea, Republic of
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Vaccine Therapy in Treating Patients With Lymphoplasmacytic Lymphoma

Lymphoplasmacytic Lymphoma

United States
Fondazione Italiana Linfomi - ETS

Active, not recruiting

Non-invasive Diagnostics and Monitoring of MRD and Clonal Evolution in Waldenström's Macroglobulinemia and in IgM-MGUS (FIL_BIOWM)

Waldenstrom Macroglobulinemia

Italy
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0309, Repository: Blood/Bone Marrow From Pts. With Myeloma, WM, Amyloidosis, or MGUS.

Multiple Myeloma | Amyloidosis | Waldenstrom's Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance | Smoldering Myeloma

United States
Yale University

Completed

Study of High-dose Influenza Vaccine Efficacy by Repeated Dosing IN Gammopathy Patients (SHIVERING 2)

Multiple Myeloma | Influenza | Waldenstrom's Macroglobulinemia | MGUS | Plasma Cell Disorders

United States
Centre Hospitalier Universitaire, Amiens
Centre Henri Becquerel; University Hospital, Caen; University Hospital, Lille; Centre... and other collaborators

Recruiting

Clinical Study of the Hyperviscosity Syndrome in Waldenström Macroglobulinemia (SLPRaresHvisc)

Waldenstrom Macroglobulinemia | Hyperviscosity Syndrome

France
Millennium Pharmaceuticals, Inc.

Completed

Dose Escalation Study of MLN0128 in Relapsed or Refractory Multiple Myeloma or Waldenstrom Macroglobulinemia

Waldenstrom Macroglobulinemia | Refractory Multiple Myeloma | Relapsed Multiple Myeloma

United States
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
Garden State Cancer Center at the Center for Molecular...
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Lymphoma or Waldenstrom's Macroglobulinemia

Lymphoma | Leukemia

United States
Shayna Sarosiek, MD
AstraZeneca

Recruiting

ACALA-R In Predominantly Demyelinating IgM Mediated Neuropathy

Waldenstrom Macroglobulinemia | Neuropathy;Peripheral | IgM MGUS

United States
Assistance Publique - Hôpitaux de Paris
INSERM UMR 1163

Not yet recruiting

Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies (GEN-HEMO-INF)

Multiple Myeloma | Waldenstrom Macroglobulinemia | Monoclonal Gammopathy of Undetermined Significance

France
Kami Maddocks, MD
Novartis

Completed

Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone... and other conditions

United States
TG Therapeutics, Inc.

Terminated

Ublituximab in Combination With Lenalidomide in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Small Lymphocytic Lymphoma | B-cell Lymphomas

United States
Amgen

Terminated

Open-label Study of the Safety and Activity of Oprozomib in Patients With Hematologic Malignancies

Multiple Myeloma | Waldenstrom Macroglobulinemia

United States
Mustang Bio
National Cancer Institute (NCI)

Recruiting

Study to Assess Safety, Tolerability and Efficacy of MB-106 in Patients With Relapsed or Refractory B-Cell NHL or CLL

Mantle Cell Lymphoma Recurrent | Mantle Cell Lymphoma Refractory | Small Lymphocytic Lymphoma, Relapsed | Waldenstrom's Macroglobulinemia Recurrent | Follicular B-cell Non-Hodgkin's Lymphoma | B-cell Lymphoma Refractory | Waldenstrom's Macroglobulinemia Refractory | Chronic Lymphoid Leukemia in Relapse

United States
Yazeed Sawalha

Withdrawn

Lenalidomide, Umbralisib, and Ublituximab for the Treatment of Relapsed or Refractory Indolent Non-Hodgkin Lymphoma or Mantle Cell Lymphoma

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma | Recurrent Grade 3a Follicular Lymphoma | Refractory Grade 1 Follicular... and other conditions
National Cancer Institute (NCI)

Terminated

Arsenic Trioxide in Treating Patients With Relapsed or Refractory Lymphoma or Leukemia

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic... and other conditions

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody Plus Rituximab With and Without Filgrastim and Interleukin-11 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone... and other conditions

United States
Acrotech Biopharma Inc.

Completed

Study of Pralatrexate & Gemcitabine With B12 & Folic Acid to Treat Relapsed/Refractory Lymphoproliferative Malignancies

B-cell Lymphoma | Hodgkin's Lymphoma | Relapsed or Refractory Lymphoproliferative Malignancies | Peripheral T-cell Lymphoma | Waldenstrom's Macroglobulinemia

United States
German CLL Study Group

Completed

Fludarabine and Cyclophosphamide in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Chronic Lymphocytic Leukemia or Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia

Canada, Germany
Mayo Clinic
National Cancer Institute (NCI)

Completed

Pembrolizumab Alone or With Idelalisib or Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Other Low-Grade B-Cell Non-Hodgkin Lymphomas

Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Refractory B-Cell Non-Hodgkin Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent B-Cell Non-Hodgkin Lymphoma and other conditions

United States
University of Vermont
National Cancer Institute (NCI)

Completed

Dolastatin 10 in Treating Patients With Indolent Lymphoma, Waldenstrom's Macroglobulinemia, or Chronic Lymphocytic Leukemia

Lymphoma | Leukemia

United States
TG Therapeutics, Inc.

Completed

Study of the Efficacy and Safety of Ublituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

B-cell Lymphoma | Marginal Zone Lymphoma | Primary Central Nervous System Lymphoma | Waldenstrom's Macroglobulinemia | Non-Hodgkins Lymphoma | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL)

United States
Acerta Pharma BV
Merck Sharp & Dohme LLC

Active, not recruiting

ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies (KEYNOTE145)

Multiple Myeloma | Hodgkin Lymphoma | Waldenström Macroglobulinemia | Burkitt Lymphoma | Small Lymphocytic Lymphoma (SLL) | Hairy Cell Leukemia | CLL | Mantle Cell Lymphoma (MCL) | Follicular Lymphoma (FL) | Richter's Syndrome | Indolent Non Hodgkin Lymphoma | Marginal Zone Lymphomas | Mediastinal Large B Cell...

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Genetically Engineered Lymphocytes, Cyclophosphamide, and Aldesleukin in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or Indolent B-Cell Non-Hodgkin Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenström Macroglobulinemia and other conditions

United States
National Cancer Institute (NCI)

Completed

Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Recurrent Small Lymphocytic Lymphoma | Recurrent Non-Hodgkin Lymphoma | Refractory Non-Hodgkin Lymphoma | Refractory Mantle Cell Lymphoma | Refractory Small Lymphocytic Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular... and other conditions

United States

Clinical Trials on Waldenstrom Macroglobulinemia (WM)

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Nigeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations